ADT has been indicated for the treatment of locally advanced or metastatic prostate cancer and includes luteinizing hormone-releasing hormone (LHRH) agonists and/or androgen receptor (AR) antagonists [13]. Here, AR is linked to metastatic prostate carcinoma.